BioArctic präsentiert Poster zu Lecanemabs Bindungsprofil auf CTAD-Kongress
- BioArctic nimmt vom 16. bis 19. November 2026 am Kongress Clinical Trials on Alzheimer's Disease (CTAD) in Boston teil.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 202610300300BITN____UKPR__SV_20261030-BIT-2296-0) on October 30, 2026, and is solely responsible for the information contained therein.